GOT1 and metabolic dysfunction-associated steatotic liver disease: More strikingly, 26 (51%) of MASLD patients had AST ≥45 IU/L, compared to only 19 (19.2%) of those without MASLD (p < 0.001), suggesting a significant liver enzyme elevation associated with MASLD (Table 3).